# Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

> **NCT00118235** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 72 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** irinotecan hydrochloride
- **BIOLOGICAL:** bevacizumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00118235
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-04
- **Final completion:** 2011-07
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118235, "Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00118235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*